Reviews and Expert Analysis · industry-kpi

What are the key sales KPIs for the Clinical Trial Site Network industry in 2027?

👁 0 views📖 1,961 words⏱ 9 min read5/30/2026

Direct Answer

The nine KPIs that actually run a Clinical Trial Site Network in 2027 are: Site Count, Patient Enrollment per Study, Enrollment Rate (Days to FPFV), Randomization Rate, Site-Activation Cycle Time, Sponsor/CRO Win Rate, Patient Retention %, EDC Query Rate, and Screen-Failure Rate, with Study Revenue per Site as the financial tenth that every PE owner watches monthly.

Together these answer the only two questions a sponsor or CRO asks before placing a study: can you enroll on time, and will the data come back clean.

TL;DR
— Sites win studies on enrollment speed, keep them on data quality, and earn margin on patient retention. If days to First Patient First Visit (FPFV) drift past 120 days or screen-failure rate climbs above 40%, sponsors quietly re-allocate the next protocol. Track the ten KPIs weekly per site, benchmark monthly against SCRS and ACRP peer data, and re-baseline therapeutic mix quarterly — that is the operating cadence Velocity Clinical Research, Headlands Research, and Care Access converged on after the 2024-2025 site-consolidation wave.

Why Clinical Trial Site Networks Work Differently

A site network is not a CRO and it is not a physician practice, even though it shares characteristics of both. Four mechanics make the model its own category.

Enrollment is the only product. Sponsors pay for one thing: randomized patients who complete the protocol. Industry data shows roughly 80% of clinical trials fail to enroll on time and the median trial finishes patient recruitment ~90 days late. A site network that beats the median by 30 days is a network sponsors call first for the next protocol.

Velocity Clinical Research publicly enrolled all 1,000 participants across 24 sites for a single trial concluded in November 2024 — the kind of result that becomes the bid-defense story for the next 18 months.

Site activation is the hidden cycle-time killer. Industry benchmarks still show 2+ months to select a site and 8 more months from selection to activation at the median, meaning trials often burn a calendar year before the first patient walks in. Networks that compress this to 120-150 days median FPFV win disproportionate share.

Accelerated start-up case studies have delivered 160 site activations in a median of 133 days — proof that the median is a choice, not a constraint.

Screen-failure rate is the silent margin tax. Industry screen-failure rates run 20%-80% depending on indication. A 2025 industry analysis put the direct cost of >40% screen-failure rates at ~$1.2M per study in wasted coordinator time, site activation cost, and patient travel reimbursement.

Oncology Phase 1 trials regularly run 50%+ screen failure; well-run cardiometabolic sites can hold it under 25%. The number the sponsor sees on the dashboard is the number that determines whether you get the next protocol.

Patient retention compounds across studies. A patient who completes one study at your site is 3x to 5x more likely to enroll in the next. Networks that own the patient relationship — through registries, recall lists, and longitudinal EHR integration — convert one-time participants into multi-study contributors.

Elligo Health Research built its model around this directly; Sanguine Bio and Javara both layer point-of-care recruitment on top of existing physician practices for the same effect.

The 9 KPIs, In Depth

1. Site Count. Total active investigator sites in the network. Velocity Clinical Research runs 80+ sites across the US, UK, and Europe; Headlands Research operates 35+ sites across North America (recently recapitalized by THL Partners in August 2025); Centricity Research runs 40+ sites across North America; Care Access runs a hybrid model with fixed and mobile units in 30+ states.

Raw count is a starting point — the relevant cut is sites by therapeutic area and by sponsor relationship.

2. Patient Enrollment per Study. Randomized patients delivered per study per site. Best-in-class operators deliver 8-15 patients per site for a typical Phase III; below 4 patients per site the sponsor flags the site as underperforming. The network-level number is the sum that goes into RFP responses.

3. Enrollment Rate (Days to FPFV). Time from site activation to first randomized patient. Industry median is 30-45 days post-activation; best-in-class networks hit 14-21 days. This is the metric sponsors actually optimize against because it is the gate to the entire enrollment curve.

4. Randomization Rate. Randomized patients per site per month, by therapeutic area. Vaccine and cardiometabolic studies regularly hit 6-12 randomizations per site per month; oncology averages 0.5-2 per site per month; rare disease can be 0.1-0.5.

The mix shift toward oncology and rare disease since 2022 has reset what "good" looks like.

5. Site-Activation Cycle Time. Days from site selection to IRB approval and Site Initiation Visit (SIV) complete. Industry median sits at 8 months; accelerated networks compress to 133-150 days. Driven by IRB cycle, contract negotiation, and regulatory packet completeness — all controllable with the right ops team.

6. Sponsor/CRO Win Rate. Studies awarded divided by studies the network was qualified for. Top independent networks run 40%-55% win rate with top-20 pharma and 25%-35% with emerging biotech. Tracked by sponsor, by CRO partner (IQVIA, ICON, Parexel, Fortrea, Medpace), and by therapeutic area — same decomposition as the CRO side.

7. Patient Retention %. Patients who complete the protocol divided by patients randomized. Best-in-class is 90%+ for short oncology and infectious disease studies, 80%-85% for 12-month metabolic studies, and 70%-80% for multi-year rare-disease programs. Drop-out per visit by week is the leading indicator.

8. EDC Query Rate. Electronic Data Capture queries opened per case report form (CRF) page. Industry median is 0.7-1.2 queries per CRF page; clean sites hold under 0.5; problem sites run 2+. The number sponsors and CROs cite back to the site at every monthly study meeting and the single best proxy for data quality.

9. Screen-Failure Rate. Patients screened who do not randomize, as a percent of total screened. Industry median is 35%-50%; tight protocols and well-trained sites hit 20%-30%; oncology Phase 1 regularly runs 50%+. Above 40% the sponsor is paying you to interview people who never enroll, and the contract economics break.

flowchart TD A[Sponsor / CRO RFP] --> B{Network Bid Defense} B -->|Win 40-55%| C[Study Award] B -->|Lose| D[Feedback Loop to BD] C --> E[Site Activation 120-150 Days] E --> F[First Patient First Visit FPFV] F --> G[Patient Screening Pipeline] G --> H{Screen Failure Filter} H -->|Pass 60-70%| I[Randomization] H -->|Fail 30-40%| J[Lost Screening Cost] I --> K{Retention Through Protocol} K -->|Complete 80-90%| L[Clean Data + Sponsor Repeat Business] K -->|Drop-Out 10-20%| M[Margin Erosion] L --> N[EDC Queries Resolved + Database Lock] N --> O[Study Revenue Recognized per Site] O --> A

Real Operators

Velocity Clinical Research (GHO Capital backed) is the scale leader with 80+ owned sites and the VISION technology platform layered on top. Headlands Research runs 35+ sites across North America, recapitalized by THL Partners in August 2025 with a thesis on owned-network scale.

Centricity Research built one of the largest North American networks via roll-up and runs 40+ sites across the US and Canada. Flourish Research (Webster Equity Partners) operates roughly 30 sites focused on cardiometabolic and CNS. Javara sits inside health systems including Atrium Health and Tufts Medicine, using point-of-care embedding to drive enrollment.

Sanguine Bio runs a decentralized model around biosample collection and patient registries. Elligo Health Research pioneered the "Direct-to-Patient" model leveraging existing physician practices and EHRs. Care Access runs a hybrid fixed-and-mobile model active in 30+ states, expanded during the COVID-19 vaccine trials and never contracted.

Acurian (PPD/Thermo Fisher) and PMG Research are the legacy comparables; Hyperion Clinical Research and AES Clinical round out the specialist mid-tier.

Failure Modes

The four ways site networks blow themselves up. (1) Activation drift — letting median Site Initiation Visit time creep past 180 days; once sponsors mark a network as "slow to start" the win rate drops 8-12 points and takes 6 quarters to rebuild. (2) Screen-failure denial — accepting >40% screen-failure rates on protocols the network should have negotiated tighter eligibility on; the $1.2M per-study cost penalty falls on the network in shared-risk contracts.

(3) PI turnover — losing a top-quartile Principal Investigator (PI) without succession; PI relationships drive 30%-40% of sponsor preference, and replacing one without site downtime takes 12-18 months. (4) Therapeutic over-concentration — building 70% of revenue around a single hot indication (long COVID, GLP-1, post-vaccine boosters) and watching demand evaporate inside two quarters when the protocol pipeline shifts.

Reporting Cadence

Daily: patient screening pipeline, randomizations, EDC query queue, no-show rate. Weekly: enrollment versus sponsor target by study, screen-failure rate by indication, site-activation milestones in flight, FPFV countdown for activating studies. Monthly: sponsor/CRO win rate, retention by study and visit number, study revenue per site, PI productivity, peer benchmarks against SCRS and ACRP.

Quarterly: therapeutic mix, sponsor concentration, network-wide capacity utilization, new-site pipeline, P&L per site for PE board reporting.

flowchart TD A[Daily Site Telemetry] --> B[Screenings + Randomizations + EDC Queries] B --> C[Weekly Study Operations Review] C --> D[Enrollment vs Target + Screen-Fail + Activation Status] D --> E[Monthly Network Business Review] E --> F[Win Rate + Retention + Revenue per Site + PI Productivity] F --> G[Quarterly Board + PE Reporting] G --> H[TA Mix + Sponsor Concentration + Capacity + Site Pipeline] H --> I[Re-Forecast + Investment + Bid-Defense Reset] I --> A

30/60/90 Day Plan

Days 1-30: instrument the ten KPIs per site and per study. Reconcile patient counts across CTMS, EDC, and finance — they will not match, and the variance is the first finding. Establish baseline site-activation cycle time, screen-failure rate by indication, and EDC query rate by therapeutic area.

Pull SCRS, ACRP, and CenterWatch peer benchmarks for context.

Days 31-60: ship the per-site scorecard with FPFV, randomization-per-month, retention, query rate, and revenue. Identify the bottom-quartile sites on enrollment velocity and either coach to median or rotate the PI relationship. Build the sponsor-by-CRO win-rate matrix and brief Business Development on the soft spots — usually emerging biotech work routed through second-tier CROs.

Days 61-90: stand up the activation acceleration playbook (IRB pre-submission templates, contract pre-negotiation with top 5 CROs, regulatory packet checklist). Set a network-wide 150-day median activation target and a <30% screen-failure target by indication. Re-baseline therapeutic mix toward oncology and rare disease per the 2026 RFP pipeline and present the new operating model to the PE board.

FAQ

Is FPFV or median activation the better speed KPI? Days to FPFV from site selection is the metric sponsors actually score on. Median activation alone hides the gap between IRB approval and the first randomized patient, which is where most network underperformance lives.

How should we benchmark screen-failure rate across indications? Always against same-indication, same-phase peer data — SCRS and ACRP both publish percentile bands. A 45% screen-failure rate is excellent for oncology Phase 1, terrible for cardiometabolic Phase 3. Cross-indication averages are operationally meaningless.

What's the right network-wide win rate target? 45%-50% with established CRO partners (IQVIA, ICON, Parexel, Fortrea) on protocols inside the network's core therapeutic areas. Below 35% for two consecutive quarters means the bid-defense story is stale or pricing is out of band.

When does EDC query rate become a sponsor relationship problem? Sustained >1.5 queries per CRF page over two studies. At that point the CRO data-management team starts flagging your sites in monthly governance meetings, and the next protocol gets routed elsewhere quietly — the network rarely hears the rejection until 6 months later.

Sources

ACRP — Association of Clinical Research Professionals, Site Performance Benchmarks
SCRS — Society for Clinical Research Sites, Annual Site Industry Survey
CenterWatch — Investigator Site Surveys and Sponsor Performance Benchmarks
Tufts Center for the Study of Drug Development — Site Performance and Cycle-Time Reports
ClinicalTrials.gov — Trial Registry and Site Activation Data
WCG Avoca — Site Quality and Sponsor Oversight Benchmarks
Velocity Clinical Research — VISION Platform and Network Performance Disclosures
Headlands Research / THL Partners — August 2025 Recapitalization Announcement
BekHealth — Top Clinical Trial Enrollment Metrics 2026 Industry Report
ProofPilot and Secondary.ai — Screen-Failure Rate Industry Analyses

Keep reading

Download:

### Direct Answer

The nine KPIs that actually run a Clinical Trial Site Network in 2027 are: **Site Count**, **Patient Enrollment per Study**, **Enrollment Rate (Days to FPFV)**, **Randomization Rate**, **Site-Activation Cycle Time**, **Sponsor/CRO Win Rate**, **Patient Retention %**, **EDC Query Rate**, and **Screen-Failure Rate**, with **Study Revenue per Site** as the financial tenth that every PE owner watches monthly. Together these answer the only two questions a sponsor or CRO asks before placing a study: can you enroll on time, and will the data come back clean.

> **TL;DR** — Sites win studies on enrollment speed, keep them on data quality, and earn margin on patient retention. If days to **First Patient First Visit (FPFV)** drift past **120 days** or screen-failure rate climbs above **40%**, sponsors quietly re-allocate the next protocol. Track the ten KPIs weekly per site, benchmark monthly against SCRS and ACRP peer data, and re-baseline therapeutic mix quarterly — that is the operating cadence Velocity Clinical Research, Headlands Research, and Care Access converged on after the 2024-2025 site-consolidation wave.

## Why Clinical Trial Site Networks Work Differently

A site network is not a CRO and it is not a physician practice, even though it shares characteristics of both. Four mechanics make the model its own category.

**Enrollment is the only product.** Sponsors pay for one thing: randomized patients who complete the protocol. Industry data shows roughly **80% of clinical trials fail to enroll on time** and the median trial finishes patient recruitment **~90 days late**. A site network that beats the median by **30 days** is a network sponsors call first for the next protocol. Velocity Clinical Research publicly enrolled **all 1,000 participants across 24 sites for a single trial concluded in November 2024** — the kind of result that becomes the bid-defense story for the next 18 months.

**Site activation is the hidden cycle-time killer.** Industry benchmarks still show **2+ months to select a site and 8 more months from selection to activation** at the median, meaning trials often burn a calendar year before the first patient walks in. Networks that compress this to **120-150 days median FPFV** win disproportionate share. Accelerated start-up case studies have delivered **160 site activations in a median of 133 days** — proof that the median is a choice, not a constraint.

**Screen-failure rate is the silent margin tax.** Industry screen-failure rates run **20%-80%** depending on indication. A 2025 industry analysis put the **direct cost of >40% screen-failure rates at ~$1.2M per study** in wasted coordinator time, site activation cost, and patient travel reimbursement. Oncology Phase 1 trials regularly run **50%+ screen failure**; well-run cardiometabolic sites can hold it under **25%**. The number the sponsor sees on the dashboard is the number that determines whether you get the next protocol.

**Patient retention compounds across studies.** A patient who completes one study at your site is **3x to 5x** more likely to enroll in the next. Networks that own the patient relationship — through registries, recall lists, and longitudinal EHR integration — convert one-time participants into multi-study contributors. **Elligo Health Research** built its model around this directly; **Sanguine Bio** and **Javara** both layer point-of-care recruitment on top of existing physician practices for the same effect.

## The 9 KPIs, In Depth

**1. Site Count.** Total active investigator sites in the network. **Velocity Clinical Research** runs **80+ sites** across the US, UK, and Europe; **Headlands Research** operates **35+ sites** across North America (recently recapitalized by THL Partners in August 2025); **Centricity Research** runs **40+** sites across North America; **Care Access** runs a hybrid model with **fixed and mobile units in 30+ states**. Raw count is a starting point — the relevant cut is sites by therapeutic area and by sponsor relationship.

**2. Patient Enrollment per Study.** Randomized patients delivered per study per site. Best-in-class operators deliver **8-15 patients per site for a typical Phase III**; below **4 patients per site** the sponsor flags the site as underperforming. The network-level number is the sum that goes into RFP responses.

**3. Enrollment Rate (Days to FPFV).** Time from site activation to first randomized patient. Industry median is **30-45 days post-activation**; best-in-class networks hit **14-21 days**. This is the metric sponsors actually optimize against because it is the gate to the entire enrollment curve.

**4. Randomization Rate.** Randomized patients per site per month, by therapeutic area. Vaccine and cardiometabolic studies regularly hit **6-12 randomizations per site per month**; oncology averages **0.5-2 per site per month**; rare disease can be **0.1-0.5**. The mix shift toward oncology and rare disease since 2022 has reset what "good" looks like.

**5. Site-Activation Cycle Time.** Days from site selection to IRB approval and Site Initiation Visit (SIV) complete. Industry median sits at **8 months**; accelerated networks compress to **133-150 days**. Driven by IRB cycle, contract negotiation, and regulatory packet completeness — all controllable with the right ops team.

**6. Sponsor/CRO Win Rate.** Studies awarded divided by studies the network was qualified for. Top independent networks run **40%-55% win rate** with top-20 pharma and **25%-35%** with emerging biotech. Tracked by sponsor, by CRO partner (IQVIA, ICON, Parexel, Fortrea, Medpace), and by therapeutic area — same decomposition as the CRO side.

**7. Patient Retention %.** Patients who complete the protocol divided by patients randomized. Best-in-class is **90%+ for short oncology and infectious disease studies**, **80%-85% for 12-month metabolic studies**, and **70%-80% for multi-year rare-disease programs**. Drop-out per visit by week is the leading indicator.

**8. EDC Query Rate.** Electronic Data Capture queries opened per case report form (CRF) page. Industry median is **0.7-1.2 queries per CRF page**; clean sites hold under **0.5**; problem sites run **2+**. The number sponsors and CROs cite back to the site at every monthly study meeting and the single best proxy for data quality.

**9. Screen-Failure Rate.** Patients screened who do not randomize, as a percent of total screened. Industry median is **35%-50%**; tight protocols and well-trained sites hit **20%-30%**; oncology Phase 1 regularly runs **50%+**. Above **40%** the sponsor is paying you to interview people who never enroll, and the contract economics break.

```mermaid
flowchart TD
    A[Sponsor / CRO RFP] --> B{Network Bid Defense}
    B -->|Win 40-55%| C[Study Award]
    B -->|Lose| D[Feedback Loop to BD]
    C --> E[Site Activation 120-150 Days]
    E --> F[First Patient First Visit FPFV]
    F --> G[Patient Screening Pipeline]
    G --> H{Screen Failure Filter}
    H -->|Pass 60-70%| I[Randomization]
    H -->|Fail 30-40%| J[Lost Screening Cost]
    I --> K{Retention Through Protocol}
    K -->|Complete 80-90%| L[Clean Data + Sponsor Repeat Business]
    K -->|Drop-Out 10-20%| M[Margin Erosion]
    L --> N[EDC Queries Resolved + Database Lock]
    N --> O[Study Revenue Recognized per Site]
    O --> A
```

## Real Operators

**Velocity Clinical Research** (GHO Capital backed) is the scale leader with **80+ owned sites** and the VISION technology platform layered on top. **Headlands Research** runs **35+ sites** across North America, recapitalized by THL Partners in August 2025 with a thesis on owned-network scale. **Centricity Research** built one of the largest North American networks via roll-up and runs **40+ sites** across the US and Canada. **Flourish Research** (Webster Equity Partners) operates roughly **30 sites** focused on cardiometabolic and CNS. **Javara** sits inside health systems including **Atrium Health and Tufts Medicine**, using point-of-care embedding to drive enrollment. **Sanguine Bio** runs a decentralized model around biosample collection and patient registries. **Elligo Health Research** pioneered the "Direct-to-Patient" model leveraging existing physician practices and EHRs. **Care Access** runs a hybrid fixed-and-mobile model active in **30+ states**, expanded during the COVID-19 vaccine trials and never contracted. **Acurian** (PPD/Thermo Fisher) and **PMG Research** are the legacy comparables; **Hyperion Clinical Research** and **AES Clinical** round out the specialist mid-tier.

## Failure Modes

The four ways site networks blow themselves up. **(1) Activation drift** — letting median Site Initiation Visit time creep past **180 days**; once sponsors mark a network as "slow to start" the win rate drops 8-12 points and takes 6 quarters to rebuild. **(2) Screen-failure denial** — accepting >40% screen-failure rates on protocols the network should have negotiated tighter eligibility on; the **$1.2M per-study** cost penalty falls on the network in shared-risk contracts. **(3) PI turnover** — losing a top-quartile Principal Investigator (PI) without succession; PI relationships drive **30%-40% of sponsor preference**, and replacing one without site downtime takes 12-18 months. **(4) Therapeutic over-concentration** — building 70% of revenue around a single hot indication (long COVID, GLP-1, post-vaccine boosters) and watching demand evaporate inside two quarters when the protocol pipeline shifts.

## Reporting Cadence

**Daily:** patient screening pipeline, randomizations, EDC query queue, no-show rate. **Weekly:** enrollment versus sponsor target by study, screen-failure rate by indication, site-activation milestones in flight, FPFV countdown for activating studies. **Monthly:** sponsor/CRO win rate, retention by study and visit number, study revenue per site, PI productivity, peer benchmarks against SCRS and ACRP. **Quarterly:** therapeutic mix, sponsor concentration, network-wide capacity utilization, new-site pipeline, P&L per site for PE board reporting.

```mermaid
flowchart TD
    A[Daily Site Telemetry] --> B[Screenings + Randomizations + EDC Queries]
    B --> C[Weekly Study Operations Review]
    C --> D[Enrollment vs Target + Screen-Fail + Activation Status]
    D --> E[Monthly Network Business Review]
    E --> F[Win Rate + Retention + Revenue per Site + PI Productivity]
    F --> G[Quarterly Board + PE Reporting]
    G --> H[TA Mix + Sponsor Concentration + Capacity + Site Pipeline]
    H --> I[Re-Forecast + Investment + Bid-Defense Reset]
    I --> A
```

## 30/60/90 Day Plan

**Days 1-30:** instrument the ten KPIs per site and per study. Reconcile patient counts across CTMS, EDC, and finance — they will not match, and the variance is the first finding. Establish baseline site-activation cycle time, screen-failure rate by indication, and EDC query rate by therapeutic area. Pull SCRS, ACRP, and CenterWatch peer benchmarks for context.

**Days 31-60:** ship the per-site scorecard with FPFV, randomization-per-month, retention, query rate, and revenue. Identify the bottom-quartile sites on enrollment velocity and either coach to median or rotate the PI relationship. Build the sponsor-by-CRO win-rate matrix and brief Business Development on the soft spots — usually emerging biotech work routed through second-tier CROs.

**Days 61-90:** stand up the activation acceleration playbook (IRB pre-submission templates, contract pre-negotiation with top 5 CROs, regulatory packet checklist). Set a network-wide **150-day median activation target** and a **<30% screen-failure target** by indication. Re-baseline therapeutic mix toward oncology and rare disease per the 2026 RFP pipeline and present the new operating model to the PE board.

## FAQ

**Is FPFV or median activation the better speed KPI?** Days to **FPFV** from site selection is the metric sponsors actually score on. Median activation alone hides the gap between IRB approval and the first randomized patient, which is where most network underperformance lives.

**How should we benchmark screen-failure rate across indications?** Always against same-indication, same-phase peer data — SCRS and ACRP both publish percentile bands. A **45% screen-failure rate** is excellent for oncology Phase 1, terrible for cardiometabolic Phase 3. Cross-indication averages are operationally meaningless.

**What's the right network-wide win rate target?** **45%-50%** with established CRO partners (IQVIA, ICON, Parexel, Fortrea) on protocols inside the network's core therapeutic areas. Below **35%** for two consecutive quarters means the bid-defense story is stale or pricing is out of band.

**When does EDC query rate become a sponsor relationship problem?** Sustained **>1.5 queries per CRF page** over two studies. At that point the CRO data-management team starts flagging your sites in monthly governance meetings, and the next protocol gets routed elsewhere quietly — the network rarely hears the rejection until 6 months later.

## Sources

- ACRP — Association of Clinical Research Professionals, Site Performance Benchmarks
- SCRS — Society for Clinical Research Sites, Annual Site Industry Survey
- CenterWatch — Investigator Site Surveys and Sponsor Performance Benchmarks
- Tufts Center for the Study of Drug Development — Site Performance and Cycle-Time Reports
- ClinicalTrials.gov — Trial Registry and Site Activation Data
- WCG Avoca — Site Quality and Sponsor Oversight Benchmarks
- Velocity Clinical Research — VISION Platform and Network Performance Disclosures
- Headlands Research / THL Partners — August 2025 Recapitalization Announcement
- BekHealth — Top Clinical Trial Enrollment Metrics 2026 Industry Report
- ProofPilot and Secondary.ai — Screen-Failure Rate Industry Analyses

Was this helpful?

Related in the library